Hospital
Alliance Healthcare System, INC
Alliance Healthcare System, INC was paid $1.17M by Medicaid between Jan 2018 and Nov 2024, across 94 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoALLIANCE HEALTHCARE SYSTEM, INC
HOLLY SPRINGS, MS 38634
HOLLY SPRINGS, MS 38634
33aNPI1295826337assigned 09/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.17M
24GClaims34,335
24DCodes billed94
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#48 of 77
Median peer was paid$8.23M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,280 | $354K | |
| 2019 | 6,360 | $183K | |
| 2020 | 3,226 | $130K | |
| 2021 | 6,208 | $166K | |
| 2022 | 6,469 | $164K | |
| 2023 | 2,916 | $145K | |
| 2024incomplete | 876 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 3,870 | 3,016 | $395K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 1,269 | 1,016 | $199K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.0% | 471 | 415 | $105K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 8.4% | 2,666 | 2,058 | $99K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.7% | 2,156 | 1,728 | $67K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 858 | 658 | $55K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.8% | 667 | 624 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.8% | 1,282 | 824 | $45K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.4% | 1,099 | 671 | $40K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.3% | 565 | 444 | $27K |
| 80053 | Comprehensive metabolic panel | 1.4% | 2,484 | 1,882 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 2,686 | 1,932 | $13K |
82 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 177 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 280 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,314 | $6K |
| 87634 | <1% | 177 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 156 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $3K |
| 87400 | <1% | 305 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 220 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 74 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 356 | $3K |
| 81001 | <1% | 1,449 | $3K | |
| 87430 | <1% | 205 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 118 | $2K |
| 85049 | <1% | 406 | $838.41 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 37 | $628.71 |
| 71045 | Radiologic examination, chest; single view | <1% | 21 | $592.55 |
| 85041 | <1% | 405 | $575.40 | |
| 85048 | <1% | 409 | $486.45 | |
| 87551 | <1% | 24 | $477.62 | |
| 85014 | <1% | 405 | $457.19 | |
| 87481 | <1% | 38 | $456.17 | |
| 85018 | <1% | 415 | $452.81 | |
| 0011A | <1% | 48 | $391.50 | |
| 0012A | <1% | 22 | $339.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38 | $166.53 |
| 82565 | <1% | 43 | $119.86 | |
| 82310 | <1% | 43 | $116.00 | |
| 84295 | <1% | 44 | $112.58 | |
| 87556 | <1% | 12 | $112.53 | |
| 84132 | <1% | 44 | $111.28 | |
| 82374 | <1% | 43 | $109.75 | |
| 84460 | <1% | 37 | $109.71 | |
| 84075 | <1% | 37 | $107.18 | |
| 84450 | <1% | 37 | $107.18 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 15 | $105.27 |
| 87541 | <1% | 12 | $105.27 | |
| 87581 | <1% | 13 | $105.27 | |
| 87486 | <1% | 13 | $105.27 | |
| 82435 | <1% | 41 | $103.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,127 | $97.61 |
| 82040 | <1% | 37 | $93.58 | |
| 0001A | <1% | 18 | $93.00 | |
| 84520 | <1% | 41 | $89.00 | |
| 81025 | <1% | 14 | $81.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 63 | $79.61 |
| 84155 | <1% | 37 | $75.90 | |
| 84484 | <1% | 26 | $72.93 | |
| 82247 | <1% | 23 | $67.80 | |
| 83690 | <1% | 16 | $65.10 | |
| 82947 | <1% | 25 | $56.64 | |
| 83992 | <1% | 51 | $54.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 209 | $14.44 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 235 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 78 | $0.00 |
| G0467 | Community health center visit, returning patient | 0% | 206 | $0.00 |
| 99335 | 0% | 352 | $0.00 | |
| 80359 | 0% | 48 | $0.00 | |
| 82962 | 0% | 170 | $0.00 | |
| 80353 | 0% | 48 | $0.00 | |
| 80358 | 0% | 48 | $0.00 | |
| 80324 | 0% | 48 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 83 | $0.00 |
| 80357 | 0% | 19 | $0.00 | |
| 99336 | 0% | 31 | $0.00 | |
| 87631 | 0% | 203 | $0.00 | |
| 80361 | 0% | 48 | $0.00 | |
| 99173 | 0% | 13 | $0.00 | |
| 80323 | 0% | 48 | $0.00 | |
| 80348 | 0% | 48 | $0.00 | |
| 11720 | 0% | 29 | $0.00 | |
| 80365 | 0% | 48 | $0.00 | |
| 11721 | 0% | 13 | $0.00 | |
| 99334 | 0% | 900 | $0.00 | |
| 81002 | 0% | 13 | $0.00 | |
| 80354 | 0% | 48 | $0.00 | |
| 80356 | 0% | 48 | $0.00 | |
| 80369 | 0% | 25 | $0.00 | |
| 80373 | 0% | 48 | $0.00 | |
| 80372 | 0% | 47 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 17 | $0.00 |
| 80362 | 0% | 19 | $0.00 | |
| 80346 | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, PERRY (ADMINISTRATOR)
Parent organizationALLIANCE HEALTHCARE SYSTEM
| Provider | Location | Paid |
|---|---|---|
| Winchester Chiropractic INC | Winchester, KY | $496K |
| Alliance Healthcare System | Holly Springs, MS | $39K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.